Lynparza Poised For Growth With Broad Ovarian Cancer Approval
AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.
You may also be interested in...
With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.
Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.
Keytruda had a great year in 2017 with $3.8bn in sales, but some Merck investors would like to see more M&A activity to bolster the company's pipeline, relaxing dependency on the blockbuster PD-1 inhibitor. However, the company revealed $12bn in capital investments to support planned growth.